A carregar...

Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders

Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the liter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Karbasi-Afshar, R, Taheri, S
Formato: Artigo
Idioma:Inglês
Publicado em: Shahid Sadoughi University of Medical Sciences 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3921880/
https://ncbi.nlm.nih.gov/pubmed/24575284
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!